文献速递药疹与重症皮肤不良反应

HLA-B*1301与氨苯砜诱导的皮肤药物不良反应的关联:系统综述与Meta分析

Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2018-01-01

该系统综述与Meta分析检索PubMed等数据库至2017年9月12日,纳入3项研究(2项中国人群、1项泰国人群),共111例氨苯砜诱导的皮肤药物不良反应患者、1165例氨苯砜耐受者和3026例健康对照。HLA-B*1301与氨苯砜诱导的皮肤药物不良反应相关(汇总OR 43.0,95%CI 24.0-77.2),亚组分析结果相似,异质性I²=0%、P=.38。作者认为在亚洲人群氨苯砜治疗前进行HLA-B*1301基因筛查是有必要的。

要点

  • HLA-B*1301与氨苯砜诱导的皮肤药物不良反应相关,汇总OR为43.0(95%CI 24.0-77.2)。
  • 氨苯砜超敏综合征亚组OR为51.7(95%CI 16.9-158.5)。
  • 作者认为亚洲人群氨苯砜治疗前进行HLA-B*1301基因筛查是有必要的。

核心结论

  • 在氨苯砜耐受对照和健康对照中均发现HLA-B*1301与氨苯砜诱导的皮肤药物不良反应相关。
  • 作者认为,为保障患者安全,亚洲人群在氨苯砜治疗前进行HLA-B*1301基因筛查是有必要的。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、人类基因组流行病学网络和Cochrane图书馆,无语言限制,从各数据库建库至2017年9月12日。
  • 初检发现391篇文章,最终纳入3项研究(2项中国人群、1项泰国人群),均为患者先接受氨苯砜治疗后进行HLA-B*1301筛查的研究。
  • 纳入分析包括111例氨苯砜诱导的皮肤药物不良反应患者、1165例氨苯砜耐受患者和3026例健康对照;病例中男性64例、女性49例(2例患者缺失于Meta分析,分别来自3项研究中的2项),平均年龄39.7岁。
  • 采用随机效应模型计算汇总OR及95%CI,并按皮肤药物不良反应类型进行亚组分析;使用Q统计量和I²检验评估统计异质性。

主要发现

  • HLA-B*1301与氨苯砜诱导的皮肤药物不良反应相关,汇总OR为43.0(95%CI 24.0-77.2)。
  • 氨苯砜超敏综合征亚组OR为51.7(95%CI 16.9-158.5)。
  • 氨苯砜诱导的严重皮肤药物不良反应(Stevens-Johnson综合征和中毒性表皮坏死松解症[SJS/TEN]加伴嗜酸性粒细胞增多和全身症状的药疹[DRESS])亚组OR为54.0(95%CI 8.0-366.2)。
  • 氨苯砜诱导的SJS/TEN亚组OR为40.5(95%CI 2.8-591.0),氨苯砜诱导的DRESS亚组OR为60.8(95%CI 7.4-496.2)。
  • 无 heterogeneity(I²=0%,P=.38)。

关键数值与推荐

  • HLA-B*1301与氨苯砜诱导的皮肤药物不良反应关联的汇总OR为43.0(95%CI 24.0-77.2)。
  • 氨苯砜超敏综合征亚组OR为51.7(95%CI 16.9-158.5)。
  • 氨苯砜诱导的严重皮肤药物不良反应(SJS/TEN加DRESS)亚组OR为54.0(95%CI 8.0-366.2)。
  • 氨苯砜诱导的SJS/TEN亚组OR为40.5(95%CI 2.8-591.0),DRESS亚组OR为60.8(95%CI 7.4-496.2)。

临床怎么用

  • 作者认为,为保障患者安全,亚洲人群在氨苯砜治疗前进行HLA-B*1301基因筛查是有必要的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dapsone-induced hypersensitivity syndrome (DHS) is a life-threatening adverse drug reaction. Based on available epidemiologic studies, HLA genotypes may play an important role in DHS. OBJECTIVE: To assess the association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions (cADRs). DATA SOURCES: Human studies investigating associations between HLA-B*1301 and dapsone-induced cADRs were systematically searched without language restriction from the inception of each database until September 12, 2017, in PubMed, the Human Genome Epidemiology Network), and the Cochrane Library. Combinations of HLA genotypes, dapsone, and synonymous terms were used; reference lists were searched in selected articles. STUDY SELECTION: Two reviewers identified studies investigating the associations between HLA-B*1301 and dapsone-induced cADRs that reported sufficient data for calculating the frequency of HLA-B*1301 carriers among case and control patients, in which all patients received dapsone before HLA-B*1301 screening. An initial search of the databases identified 391 articles, of which 3 studies (2 in Chinese populations and 1 in a Thai population) met the inclusion criteria. DATA EXTRACTION AND SYNTHESIS: Overall odds ratios (ORs) with 95% CIs were calculated using a random-effects model to determine the association between HLA-B*1301 and dapsone-induced cADRs. Subgroup analyses by type of cADR were also performed. PRISMA guidelines were used to abstract and assess data. MAIN OUTCOMES AND MEASURES: Primary outcomes were associations between HLA-B*1301 and dapsone-induced cADRs in dapsone-tolerant controls. The outcomes are reported as overall OR. Statistical heterogeneity was assessed using the Q statistic and I2 tests. RESULTS: From the 3 included studies, there were 111 unique patients with dapsone-induced cADRs (subsequently used in the meta-analysis), 1165 dapsone-tolerant patients, and 3026 healthy controls. The cases included 64 men and 49 women (2 patients were missing from the meta-analysis; 1 each from 2 of the 3 studies); mean age was 39.7 years. An association between HLA-B*1301 and dapsone-induced cADRs was identified (summary OR, 43.0; 95% CI, 24.0-77.2). Subgroup analyses among types of cADRs produced similar findings in DHS (OR, 51.7; 95% CI, 16.9-158.5), dapsone-induced severe cADRs (Stevens-Johnson syndrome and toxic epidermal necrolysis [SJS/TEN] plus drug rash [adverse skin reaction to a drug] along with eosinophilia and systemic symptoms [DRESS]) (OR, 54.0; 95% Cl, 8.0-366.2), dapsone-induced SJS/TEN (OR, 40.5; 95% CI, 2.8-591.0), and dapsone-induced DRESS (OR, 60.8; 95% CI, 7.4-496.2). There was no heterogeneity (I2 = 0%, P = .38). CONCLUSIONS AND RELEVANCE: Associations between HLA-B*1301 and dapsone-induced cADRs were found in dapsone-tolerant and healthy control groups. For patient safety, genetic screening for HLA-B*1301 in Asian populations before dapsone therapy is warranted.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Tangamornsuksan W, Lohitnavy M. Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018. PMID: 29541744. doi:10.1001/jamadermatol.2017.6484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。